Chan Henry Lee Sells 332 Shares of BeOne Medicines (NASDAQ:ONC) Stock

Key Points

• SVP Chan Henry Lee sold 332 shares of BeOne Medicines on April 8 at an average price of $311.59 for about $103,448, reducing his stake by 0.10% to 318,370 shares valued at roughly $99.2 million.
• BeOne shares traded down to $309.66 (−1.2%) after the company missed quarterly EPS ($0.58 vs. $1.60 expected), yet Wall Street remains largely positive with 11 Buy ratings and a consensus target of $385.08.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 332 shares of the company's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $311.59, for a total value of $103,447.88. Following the sale, the senior vice president owned 318,370 shares in the company, valued at approximately $99,200,908.30. This trade represents a 0.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, March 11th, Chan Henry Lee sold 341 shares of BeOne Medicines stock. The shares were sold at an average price of $300.00, for a total value of $102,300.00.
• On Wednesday, February 4th, Chan Henry Lee sold 1,660 shares of BeOne Medicines stock. The stock was sold at an average price of $349.52, for a total value of $580,203.20.

BeOne Medicines Stock Down 1.2%

Shares of ONC stock traded down $3.76 during trading hours on Friday, reaching $309.66. 134,413 shares of the stock were exchanged, compared to its average volume of 264,760. The business's fifty day moving average is $316.84 and its two-hundred day moving average is $324.95. The firm has a market capitalization of $33.98 billion, a P/E ratio of 122.88 and a beta of 0.53. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $218.31 and a 12-month high of $385.22. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.41 and a quick ratio of 3.08.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.60 by ($1.02). BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%.The firm had revenue of $1.50 billion during the quarter, compared to analysts' expectations of $1.45 billion. As a group, research analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Wall Street Zen cut BeOne Medicines from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 28th. Sanford C. Bernstein upgraded BeOne Medicines from a "hold" rating to an "outperform" rating and set a $414.00 price objective on the stock in a report on Monday, January 12th. Jefferies Financial Group lowered BeOne Medicines from a "buy" rating to a "hold" rating and cut their target price for the stock from $420.00 to $290.00 in a research report on Monday, March 16th. Guggenheim boosted their target price on BeOne Medicines from $400.00 to $410.00 and gave the stock a "buy" rating in a research note on Friday, February 27th. Finally, Truist Financial upped their price target on BeOne Medicines from $400.00 to $412.00 and gave the company a "buy" rating in a report on Friday, February 27th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $385.08.

Institutional Trading of BeOne Medicines

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE purchased a new position in BeOne Medicines during the 2nd quarter worth approximately $67,657,000. Man Group plc purchased a new stake in BeOne Medicines in the second quarter valued at approximately $59,031,000. Capital International Investors boosted its holdings in shares of BeOne Medicines by 3.3% in the third quarter. Capital International Investors now owns 5,046,058 shares of the company's stock valued at $1,716,883,000 after acquiring an additional 161,052 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $38,337,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of BeOne Medicines during the second quarter worth approximately $26,034,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.